EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Valaciclovir therapy for secondary suppression of immune response to herpesviruses: An exploratory study

Kirsty McGee, Alex Dowell, Sarah Lauder, Jusnara Begum, Odette Chagoury, Wayne Croft, Lee Middleton, Yongzhong Sun, Jianmin Zuo, Richard McManus, Paul Moss iD

PLOS Pathogens · 2025

DOI: 10.1371/journal.ppat.1013803 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2025. Verfasst von Kirsty McGee und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom. Hauptthemen laut MEDLINE: Valine, Antiviral Agents, Acyclovir, Cytomegalovirus. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Herpesviruses establish a state of persistent infection which is suppressed by sustained virus-specific immune control. The magnitude of this immune response can increase with age and lead to attrition of immune reserve against other pathogens. Approaches which suppress herpesvirus-specific immunity may therefore have the potential to improve general immune function. Anti-retroviral therapy for HIV leads to a reduction in HIV viral antigen and has been shown to mediate a secondary attenuation of the HIV-specific immune response. As such, we assessed if treatment with valaciclovir could suppress the immune response against cytomegalovirus and Epstein Barr Virus in donors aged >65 years. Medication was given at 3 different doses up to a maximum of 4gm/day for 6 months and humoral and cellular profiles were assessed over 12 months. Anti-viral therapy did not impact on the magnitude or phenotype of the humoral or cellular virus-specific immune response during the study period. Treatment also had no impact of physical or mental quality of life assessment. These data show that valaciclovir treatment, at this dose and treatment duration, does not attenuate the CMV or EBV-specific immune response in this age group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ValineAntiviral AgentsAcyclovirCytomegalovirusHerpesvirus 4, HumanEpstein-Barr Virus InfectionsCytomegalovirus InfectionsHerpesviridae InfectionsHumansValacyclovirMaleFemaleAgedImmunity, CellularImmunity, HumoralAntibodies, ViralHerpesviridae

Substanzen

ValineValacyclovirAntiviral AgentsAcyclovirAntibodies, Viral

Autor:innen und Institutionen

  • School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom.
  • National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, United Kingdom.
  • Department of Immunology, Cardiff University, Cardiff, United Kingdom.
  • Qatar Metabolic Institute, Hamad Medical Corporation, Doha, Qatar.
  • Weill Cornell Medicine-Qatar, Doha, Qatar.
  • School of Health Sciences, University of Birmingham, Birmingham, United Kingdom.

ORCID-Profile: Paul Moss

Förderung

  • Medical Research Council

Zitieren

APA

McGee, K., Dowell, A., Lauder, S., Begum, J., Chagoury, O., Croft, W., Middleton, L., Sun, Y., Zuo, J., McManus, R., & Moss, P. (2025). Valaciclovir therapy for secondary suppression of immune response to herpesviruses: An exploratory study. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1013803

Vancouver

McGee K, Dowell A, Lauder S, Begum J, Chagoury O, Croft W, et al. Valaciclovir therapy for secondary suppression of immune response to herpesviruses: An exploratory study. PLOS Pathogens. 2025. doi:10.1371/journal.ppat.1013803

BibTeX
@article{McGee2025,
  author = {McGee, Kirsty and Dowell, Alex and Lauder, Sarah and Begum, Jusnara and Chagoury, Odette and Croft, Wayne and Middleton, Lee and Sun, Yongzhong and Zuo, Jianmin and McManus, Richard and Moss, Paul},
  title = {Valaciclovir therapy for secondary suppression of immune response to herpesviruses: An exploratory study},
  journal = {PLOS Pathogens},
  year = {2025},
  doi = {10.1371/journal.ppat.1013803}
}
Kostenlos starten →